Last reviewed 2026-04-23 · How we verify

4SC-201

4SC AG · Phase 2 active Small molecule

At a glance

Generic name	4SC-201
Sponsor	4SC AG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (PHASE2)
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (PHASE1, PHASE2)
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (PHASE2)
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results